Fabtech Technologies Cleanrooms operates a manufacturing facility in Umbergaon, which is equipped with advanced machinery to produce high-performance cleanroom partitions.
The company's manufacturing facility is equipped with process-critical machines, including a roll-forming machine for cutting and bending metal sheets to create trays of various sizes, a fully automatic Amada Punch Press CNC machine and 30 different tooling programs for making cut-outs, holes, and perforations in metal sheets for partitions and doors, a powder coating plant, an Amada Brake Press CNC machine with programmable gauge adjustment and 100-tonne capacity for bending metal sheets, and suitable puff filling and puff press machines for insulating modular cleanroom panels.
The company's clientele includes prominent pharmaceutical and healthcare companies such as Unichem Laboratories Ltd, Desano Pharmaceuticals Private Limited, Apitoria Pharma Pvt Ltd (a 100% subsidiary of Aurobindo Pharma Ltd), and Hamdard Laboratories (India).
Through its subsidiary, Altair Partition Systems LLP, Fabtech manufactures modular panels of an economical grade. Additionally, the company holds a 26% equity stake in Advantek Air Systems Private Limited, which specialises in manufacturing air handling units, a critical component for cleanroom operations.
Fabtech Technologies Cleanrooms is ISO 9001:2015 certified for quality management systems, and its cleanroom panels are approved by the FM Global group, ensuring compliance with fire safety standards.
Through investments in Advantek, Kelvin, and Altair, Fabtech claims to have developed an integrated ecosystem that offers cleanroom solutions. This includes the supply of cleanroom panels (such as wall panels, view panels, doors, risers, ceiling panels, and covings), HVAC systems, and air handling units, along with installation services.
The company has certain contingent liabilities, which amounted to Rs 5.83 crore as of September 30, 2024. If these liabilities materialise they could harm the company’s financial standing.
A major portion of the company's revenue is generated from customers operating in the pharmaceuticals, healthcare, and biotech sectors. Customers working in these sectors contributed Rs 53.13 crore (85.80%) as of September 30, 2024, and Rs 92.59 crore (95.07%), Rs 117.63 crore (94.36%), and Rs 109.89 crore (96.65%) in FY24, FY23, and FY22, respectively, to the revenue from operations. Any adverse developments in these sectors could negatively impact the company’s operations and financial performance.
The company relies on a small number of customers for a major portion of its revenue. Its top 10 customers contributed Rs 32.81 crore (52.99%) as of the six months ending September 30, 2024, and Rs 52.91 crore (54.32%), Rs 65.40 crore (52.46%), and Rs 55.97 crore (49.23%) in FY24, FY23, and FY22, respectively, to the revenue from operations. Any loss of any major client or a reduction in projects from them could adversely impact the company’s operations and finances.
The company, some of its promoters, and its directors are involved in certain ongoing legal proceedings. Any adverse judgments in any of these cases could be detrimental to the company’s business prospects.
As of September 30, 2024, the company’s total debt (both long-term and short-term) stood at Rs 3.20 crore. Any inability to repay or service these loans could adversely affect the company’s financial position.